Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis

Chung Yin Stanley Chan; John C. Browning; Fiona Larsen; Sylvia Hsu

Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis

Chung Yin Stanley Chan, John C. Browning, Fiona Larsen, Sylvia Hsu

Research output: Contribution to journal › Article › peer-review

Abstract

Infliximab is a chimeric monoclonal antibody that selectively blocks tumor necrosis factor-alpha (TNF-α). It is indicated for the treatment of numerous inflammatory diseases, including rheumatoid arthritis, Crohn disease, ulcerative colitis, ankylosing spondyilitis, and psoriatic arthritis. Infliximab has also been shown to be a well tolerated and highly effective treatment for psoriatic skin lesions. We report an interesting case of unexpected, newonset psoriasis in a patient on infliximab for rheumatoid arthritis.

Original language	English (US)
Article number	12
Journal	Dermatology online journal
Volume	14
Issue number	9
State	Published - Sep 1 2008
Externally published	Yes

ASJC Scopus subject areas

Dermatology

Fingerprint Dive into the research topics of 'Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this

@article{e1b4ce3692334e46b8332684a9b8e45a,

title = "Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis",

abstract = "Infliximab is a chimeric monoclonal antibody that selectively blocks tumor necrosis factor-alpha (TNF-α). It is indicated for the treatment of numerous inflammatory diseases, including rheumatoid arthritis, Crohn disease, ulcerative colitis, ankylosing spondyilitis, and psoriatic arthritis. Infliximab has also been shown to be a well tolerated and highly effective treatment for psoriatic skin lesions. We report an interesting case of unexpected, newonset psoriasis in a patient on infliximab for rheumatoid arthritis.",

author = "Chan, {Chung Yin Stanley} and Browning, {John C.} and Fiona Larsen and Sylvia Hsu",

year = "2008",

month = sep,

day = "1",

language = "English (US)",

volume = "14",

journal = "Dermatology Online Journal",

issn = "1087-2108",

publisher = "Department of Dermatology UC Davis",

number = "9",

}

TY - JOUR

T1 - Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis

AU - Chan, Chung Yin Stanley

AU - Browning, John C.

AU - Larsen, Fiona

AU - Hsu, Sylvia

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Infliximab is a chimeric monoclonal antibody that selectively blocks tumor necrosis factor-alpha (TNF-α). It is indicated for the treatment of numerous inflammatory diseases, including rheumatoid arthritis, Crohn disease, ulcerative colitis, ankylosing spondyilitis, and psoriatic arthritis. Infliximab has also been shown to be a well tolerated and highly effective treatment for psoriatic skin lesions. We report an interesting case of unexpected, newonset psoriasis in a patient on infliximab for rheumatoid arthritis.

AB - Infliximab is a chimeric monoclonal antibody that selectively blocks tumor necrosis factor-alpha (TNF-α). It is indicated for the treatment of numerous inflammatory diseases, including rheumatoid arthritis, Crohn disease, ulcerative colitis, ankylosing spondyilitis, and psoriatic arthritis. Infliximab has also been shown to be a well tolerated and highly effective treatment for psoriatic skin lesions. We report an interesting case of unexpected, newonset psoriasis in a patient on infliximab for rheumatoid arthritis.

UR - http://www.scopus.com/inward/record.url?scp=54549105248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54549105248&partnerID=8YFLogxK

M3 - Article

C2 - 19061594

AN - SCOPUS:54549105248

VL - 14

JO - Dermatology Online Journal

JF - Dermatology Online Journal

SN - 1087-2108

IS - 9

M1 - 12

ER -